This webinar will feature an academic case study on NaV1.9 as a drug target by Professor David Bulmer (University of Cambridge). The webinar will also include a presentation by Metrion CSO, Dr. Eddy Stevens with an overview of Metrion’s newly developed NaV1.9 screening assays.
A recent study published in the Journal of Pharmaceutical Sciences (https://doi.org/10.1016/j.xphs.2024.10.013) analysed the complexities of three-dimensional crystal packing arrangements of small-molecule drug candidates, focusing on the CCDC Solid Form Health Check to assess the risk of thermodynamically stable solid forms during drug development.
Infex is developing new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, we have a pipeline of drugs in preclinical and clinical development to treat patients suffering from life-threatening infections.
As part of the continued development of the company we are now looking to appoint an enthusiastic Finance Manager to work alongside the CFO and Finance Administrator to provide accurate and up to date financial reporting to the Board and Science Team.
Boyds is delighted to announce the appointment of Matt O’Connor who joins the company as Senior Manager, Regulatory Affairs.
Matt joins Boyds following more than five years at DLRC, where he gained broad experience across the regulatory lifecycle, supporting regulatory procedures in varied therapeutic areas. He is also a member of The Organisation for Professionals in Regulatory Affairs (TOPRA).
Seasoned executive joins PrecisionLife to drive commercial strategy for new first-in-class precision medicine tests to predict and prevent complex, chronic diseases
Applications are invited for an Alliance and Impact Manager to join the Business Development department at Quadram Institute Bioscience (QIB), based in Norwich, UK.
Background:
Location: Nottingham, UK
Read One Nucleus' eNews January issue here
With Tony Jones, One Nucleus' CEO, guiding you on your journey to success in 2025, by signposting you to:
✅ Will Your 2025 Get Off to a Flying Start?
✅ Money: Investment, Partnering & Business Development
✅ People
✅ Technology
✅ Reflections on Genesis 2024
✅ One Nucleus Annual Awards
Trigeminal neuralgia, a chronic pain disorder rooted in trigeminal nerve dysfunction, presents a substantial challenge due to its intense pain profile and the limited effectiveness of current treatments.
This webinar offer enables researchers to expand their knowledge of ion channel therapeutics, develop innovative strategies, and accelerate the development of new, more effective treatments for patients burdened by chronic trigeminal pain.
Cambridge, UK, 25 November 2024: Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Lee Patterson as its new CEO, effective from 2nd December 2024. An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets. He succeeds Dr Andrew Southan, who has decided to step down as CEO after five years in the post.